Replies to post #432741 on Amarin Corp Plc (AMRN)

[Chromosome]

My guess is they want to minimize their cash spend on buy backs although they know they may have to. As such, if they feel confident about their earnings release moving the stock in a positive direction, they may wait until after the earnings to spend least amount of money they can on buy-backs. Just a guess.

[couldbebetter]

Skipperdog, My fear is that Denner will reverse split,
wait for the drop, then have his Sarissa pick up shares
and after they get what they want they will initiate the
share buyback. Such a plan would give Denner the
most bang for the buck. "If" Denner does have an
actual plan to create value through either sales development,
a new formulation (for BP,) or a planned sale to a BP...My
guess is that he would initiate and complete a share buyback.
What disturbs me is the seeming disinterest in doing anything
that would support the share price or show a sign of AMRN
having a prosperous future. Amazing how Sarissa communicated
with shareholders when they wanted our votes, but now, nothing.

[seve333]

A reverse split would be a disaster for all of us. Denner has been a horrible disappointment. I guess its possible he still has something up his sleeve but he seems disinterested and time is now running out.

[rosemountbomber]

Whoa, thanks.  I have been saying that there is no need to maintain the listing if the goal is to sell the drug to another pharma.  If BP wants Vazkepa it matters not. 

[Whalatane]

Re

You can reverse split this 1 for 10 and I guarantee the stock is sub $1.00 in 6 months

I'll take that bet ( against U ) . Co has to much cash on hand especially if it can operate breakeven ...for it to lose 80% of its value after a R/S in 6 mths .

By the way ...all a CAD patient like moi needs is Leqvivo ( see previous post ) and Vascepa . Difference is that NVS is funding extra trials to show / confirm Leqvio's risk reduction ..and AMRN isn't

Completed major Leqvio trials to date

Below is a list of key clinical trials conducted for Leqvio (inclisiran), a small interfering RNA (siRNA) therapy used to lower LDL cholesterol:
Phase III Trials
ORION-9:
Participants: 482 patients with heterozygous familial hypercholesterolemia (HeFH).
Results: Reduced LDL-C by 48% compared to placebo at 17 months.
Design: Double-blind, placebo-controlled trial conducted across eight countries1.
ORION-10:
Participants: 1,561 patients with atherosclerotic cardiovascular disease (ASCVD).
Results: LDL-C reduction of 52% compared to placebo at 17 months.
Location: Conducted at 145 sites in the US1.
ORION-11:
Participants: 1,617 patients with ASCVD or ASCVD risk equivalents.
Results: LDL-C reduction of 50% compared to placebo at 17 months.
Location: Conducted across seven countries1.
V-MONO:
Participants: 350 patients at low or moderate ASCVD risk.
Results: Clinically meaningful LDL-C reduction compared to ezetimibe and placebo at day 150.
Design: Randomized, double-blind trial25.
Open-Label Extension Studies
ORION-3:
Extension of ORION-1 trial with 233 participants over four years.
Results: Maintained LDL-C reduction of ~47.5% at Day 210 and ~44.2% over four years with twice-yearly dosing1.
ORION-8:
Largest trial to date, with over 8,500 patient-years of exposure.
Results: Sustained LDL-C reduction (~50%) and consistent safety profile over six years4.

Kiwi